Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy Guggenheim

Regeneron Pharmaceuticals Inc.
Start price
€558.60
29.10.25 / 50%
Target price
€742.60
29.10.26
Performance (%)
24.63%
Price
€693.40
10:32
Summary
This prediction is currently active. The BUY prediction by Guggenheim currently has a performance of 24.63%. Dividends of €2.76 are taken into consideration when calculating the performance. This prediction currently runs until 29.10.26. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

AI-generated
Performance without dividends (%)
Name 1w 1m
Regeneron Pharmaceuticals Inc. 1.360% 1.360%
iShares Core DAX® -0,87 % 5,32 %
iShares Nasdaq 100 -0,38 % 1,98 %
iShares Nikkei 225® -1,68 % 1,95 %
iShares S&P 500 -0,65 % 2,07 %

Comments by Guggenheim for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) 24.63%
Target price 742.603
Change
Ends at 29.10.26

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $815.00 to $865.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat

Guggenheim 
0
Report Share
29.10.25

Stopped prediction by Guggenheim for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€660.70
03.08.26
€893.42
03.08.27
5.81%
10:32

Guggenheim 
03.08.26 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€592.20
21.07.26
€876.40
21.07.27
18.05%
10:32

Guggenheim 
21.07.26 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€651.20
09.02.26
€824.85
09.02.27
7.64%
10:32

Guggenheim 
09.02.26 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€434.90
30.05.25
-
30.05.26
20.76%
31.05.26

Guggenheim 
30.05.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€530.00
01.05.25
€716.36
01.05.26
12.32%
02.05.26

Guggenheim 
01.05.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€991.00
02.08.24
€1,190.9
02.08.25
-51.34%
03.08.25

Guggenheim 
02.08.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€973.80
19.07.24
€1,082.5
19.07.25
-51.82%
20.07.25

Guggenheim 
19.07.24 50%